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Upon antigen stimulation, naive T cells undergo extensive clonal expansion and differentiation for immune defense and regulation. A defining feature of T cell activation is the marked increase of the bioenergetic demands over the resting state. Activated T cells are highly anabolic and demonstrate a striking increase in glycolysis, as well as an increase in glucose and amino acid uptake (Fox et al., 2005; Jones and Thompson, 2007; Pearce, 2010) . The reliance on glycolysis (even in the presence of high levels of oxygen) to generate ATP, which is far less efficient than oxidative phosphorylation, is an unusual metabolic aspect of proliferating T cells and cancer cells, the latter of which is known as the Warburg effect (Warburg, 1956) . Fox et al. (2005) and Jones and Thompson (2007) have proposed that up-regulation of T cell metabolism is not merely a consequence of increased activation but rather a necessary step to facilitate activation. In support of this notion, proper regulation of glucose and sterol metabolism is required for the development of adaptive immune responses Cham et al., 2008) . Conversely, anergic T cells fail to up-regulate the machinery necessary to support increased metabolism Zheng et al., 2009) , whereas memory cell formation requires a lower metabolic activity (Araki et al., 2009; Pearce et al., 2009) . Although a role for the metabolic pathways in T cell activation and responses is beginning to be appreciated, little information exists on their involvement in the differentiation of T cell functional subsets.
Discrete effector populations can develop from naive T cells to mediate specialized immune functions and are characterized by unique patterns of cytokine secretion. IFN-, IL-4, and Upon antigen stimulation, the bioenergetic demands of T cells increase dramatically over the resting state. Although a role for the metabolic switch to glycolysis has been suggested to support increased anabolic activities and facilitate T cell growth and proliferation, whether cellular metabolism controls T cell lineage choices remains poorly understood. We report that the glycolytic pathway is actively regulated during the differentiation of inflammatory T H 17 and Foxp3-expressing regulatory T cells (T reg cells) and controls cell fate determination. T H 17 but not T reg cell-inducing conditions resulted in strong up-regulation of the glycolytic activity and induction of glycolytic enzymes. Blocking glycolysis inhibited T H 17 development while promoting T reg cell generation. Moreover, the transcription factor hypoxia-inducible factor 1 (HIF1) was selectively expressed in T H 17 cells and its induction required signaling through mTOR, a central regulator of cellular metabolism. HIF1-dependent transcriptional program was important for mediating glycolytic activity, thereby contributing to the lineage choices between T H 17 and T reg cells. Lack of HIF1 resulted in diminished T H 17 development but enhanced T reg cell differentiation and protected mice from autoimmune neuroinflammation. Our studies demonstrate that HIF1-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of T H 17 and T reg cells.
with a very recent study (Michalek et al., 2011) , T H 1, T H 2, and T H 17 cells contained much higher glycolytic activity than T reg cells (Fig. 1 A) , indicating strong up-regulation of glucose metabolism in effector T cells.
We next tested whether the differential activity of glycolysis between effector and regulatory T cells is transcriptionally regulated. A key transcription factor orchestrating the expression of glycolytic enzymes is HIF1, a heterodimer comprised of  (HIF1) and  (HIF1) subunits (Nizet and Johnson, 2009) . Although HIF1 has been implicated in T cell responses (Neumann et al., 2005; Lukashev et al., 2006) , its function and regulation in T cell differentiation remain undefined. To determine the intrinsic function of HIF1 in T cells, we first examined expression of HIF1, the regulated component of the complex. Although HIF1 is known to be induced by hypoxic conditions through a posttranslational-dependent mechanism, HIF1 can be up-regulated by NF-B signaling in activated innate immune cells under normoxia (Rius et al., 2008; Nizet and Johnson, 2009 ). HIF1 was strongly induced at the protein level in T cells undergoing T H 17 differentiation, whereas the lowest levels were found in T reg cells. Moreover, mRNA levels of HIF1 were also highly induced in T cells undergoing T H 17 differentiation (Fig. 1 B) . These results identify a selective up-regulation of HIF1 under T H 17-polarizing conditions.
To investigate the role of HIF1 in T cell differentiation, we crossed mice carrying a conditional HIF1 allele (HIF1 flox/flox ; Ryan et al., 2000) with CD4-Cre transgenic mice to delete the floxed HIF1 allele specifically in T cells (called HIF1 -/-mice thereafter). Real-time PCR analyses indicated efficient deletion of the HIF1 gene in T cells (Fig. 1 C) . WT and HIF1 / mice contained similar numbers and distribution of thymocytes and peripheral CD4 and CD8 T cells (Fig. S1 A) . Also, development and homeostasis of natural T reg cells appeared to be largely undisturbed (Fig. S1 B) . Cell proliferation and apoptosis in response to TCR stimulation were also comparable between WT and HIF1 / T cells (Fig. S1 , C and D). To examine whether HIF1 controls glycolytic activity in T H 17 cells, we purified naive T cells from WT and HIF1 / mice and differentiated them under T H 17-polarizing conditions. Deficiency in HIF1 resulted in greatly reduced glycolytic activity (Fig. 1 D) , indicating an important role for HIF1 to promote glycolysis in T H 17 differentiation.
Glucose utilization depends on a chain of reactions catalyzed by multiple enzymes, eventually leading to the generation of lactate and net production of two ATP molecules as the energy source. In addition, glucose transport 1 (Glut1) and monocarboxylic acid transporter member 4 (MCT4) serve as plasma membrane transporters for glucose uptake and lactate export, respectively (Fig. 1 E) . Real-time PCR analyses of WT cells undergoing T H 17 differentiation revealed marked up-regulation of genes encoding various molecules involved in glycolysis (Fig. 1 F) . These include the transporters Glut1 and MCT4 and glycolytic enzymes HK2 (hexokinase 2), GPI (glucose-6-phosphate isomerase), TPI (triosephosphate isomerase), Eno1 (enolase 1), PKM (pyruvate kinase muscle), and IL-17 are the signature cytokines for T H 1, T H 2, and T H 17 cells, respectively. In contrast, induced Foxp3 + regulatory T cells (T reg cells) act in synergy with natural T reg cells to promote immune tolerance and inhibit autoimmunity (Littman and Rudensky, 2010; Zhu et al., 2010) . Induction of T reg cells in the peripheral immune compartment is closely related to the generation of T H 17 cells, as the differentiation of both lineages is dependent on the pleiotropic cytokine TGF- (Bettelli et al., 2006) . Also, ROR-t and Foxp3, the respective lineagespecific transcription factors for T H 17 and T reg cells, are coexpressed in naive CD4 T cells exposed to TGF-, but Foxp3 is dominant and antagonizes ROR-t function unless IL-6 is present (Zhou et al., 2008) . Thus, an inflammatory environment controls the balance between T reg and T H 17 cell differentiation. The cytokines and environmental signals trigger a signaling cascade culminating in the transcriptional induction of lineage-specific cytokines and effector molecules. In particular, mTOR, a central regulator of cellular metabolism and protein translation, integrates various extracellular and intracellular signals to promote effector but not regulatory T cell differentiation Powell and Delgoffe, 2010) . However, it remains unknown whether the basic metabolic machinery is actively regulated and contributes to T cell differentiation.
In this paper, we show that T H 17 and T reg cells have marked differences in their glycolytic activity and expression of glycolytic enzymes. Combining pharmacological and genetic approaches, we found that glycolysis serves as a key metabolic checkpoint to direct the cell fate determination between T H 17 and T reg cells. Specifically, the glucose analogue 2-deoxyglucose (2-DG), a prototypical inhibitor of the glycolytic pathway, dampened the development of T cells into T H 17 cells while promoting T reg cell generation. In addition, deficiency in the transcription factor hypoxia-inducible factor 1 (HIF1) in T cells diminished expression of the glycolytic molecules and altered the dichotomy between these two T cell lineages. Moreover, the HIF1-dependent glycolytic pathway is downstream of mTOR signaling, thereby contributing to mTORmediated T cell differentiation. Our studies demonstrate that HIF1-induced metabolic reprogramming orchestrates lineage differentiation of T cells.
RESULTS AND DISCUSSION T H 17-polarizing conditions induce HIF1-dependent glycolytic activity
Although it has been well appreciated that T cell activation is accompanied by a metabolic switch to glycolysis (Fox et al., 2005; Jones and Thompson, 2007; Pearce, 2010) , how glycolytic activity is regulated during T cell differentiation is poorly understood. We therefore measured glycolytic activity in various CD4 T cell lineages. To this end, we activated naive T cells under polarizing conditions in vitro and obtained T H 1, T H 2, T H 17, and T reg cells with selective expression of IFN-, IL-4, IL-17, and Foxp3, respectively (Fig. 1 A) . The glycolytic activity of differentiated cells was measured by the generation of 3 H-labeled H 2 O from [3-3 H]-glucose. In agreement Br ief Definitive Repor t parable level of IL-2, relative to WT cells (Fig. 2 B) . Realtime PCR analyses revealed decreased expression of the T H 17 family cytokines IL-17, IL-17F, IL-21, and IL-22 (Fig. 2 C) . Thus, HIF1 deficiency results in impairment in the T H 17 differentiation program. In contrast, in vitro differentiation of T H 1 and T H 2 effector cells was largely independent of HIF1 ( Fig. S2 C) .
T cell differentiation is programmed by coordinated induction of transcription factors and cytokine receptors to facilitate the establishment of specific lineages (Littman and Rudensky, 2010; Zhu et al., 2010) . To identify mechanisms of defective T H 17 differentiation in HIF1 / cells, we examined the expression of transcription factors and cytokine receptors involved in T H 17 differentiation. Expression of ROR-, ROR-t, AHR, IRF4, IL-6R, and IL-21R and the phosphorylation of Stat3 were comparable between differentiating WT and HIF1 / cells (unpublished data). In contrast, expression of IL-23R was significantly down-regulated (Fig. 2 D) , whereas Foxp3 was up-regulated ( Fig. 2 E) , in HIF1 / cells under T H 17-polarizing conditions. IL-23R is essential for terminal differentiation of T H 17 cells (McGeachy et al., 2009) , whereas Foxp3, the T reg cell master regulator, has been shown to antagonize ROR-t function and T H 17 differentiation LDH- (lactate dehydrogenase), thus encompassing the entire spectrum of the glycolytic pathway. In contrast, expression levels of these molecules were much lower in HIF1 / cells cultured under similar conditions ( Fig. 1 F) . Therefore, HIF1 establishes the glycolytic gene expression program in T H 17 cells.
HIF1 is required for T H 17 differentiation
Having demonstrated a role for HIF1 in mediating glycolysis in T H 17 cells, we next explored the functional requirement of HIF1 in effector T cell differentiation. Naive T cells from WT and HIF1 / mice were differentiated under T H 17 conditions, and expression of IL-17 was examined by intracellular staining. As compared with WT cells, HIF1 / cells exhibited a reduction of IL-17 + cells (Fig. 2 A) . CFSE dilution assays revealed a similar degree of proliferation between WT and HIF1 / cells, indicating that the defective IL-17 production was largely independent of cell expansion (Fig. S2 A) . In addition, impaired IL-17 production was observed in HIF1 / cells, regardless of the inclusion of IL-23 or blocking antibodies to potentiate T H 17 differentiation (Fig. S2 B) . Furthermore, upon TCR restimulation, effector T H 17 cells lacking HIF1 secreted a lower amount of IL-17, but a com- enzymes described in Fig. 1 F, all of which were markedly down-regulated in HIF1 / cells. HIF1 / cells also showed altered expression of transcription factors, signaling molecules, and surface/secreted factors that have been implicated in T cell function and differentiation, including Gadd45, Map3k1 (MEKK1), TLR2, Tnfrsf9 (4-1BB), and, as expected, IL-17. The canonical HIF1 target gene VEGF was also diminished in HIF1 / cells (Fig. 2 G) . These findings reveal diverse HIF1 target genes in T cells that may collectively control T cell metabolism and differentiation.
To investigate the physiological significance of HIF1 in vivo, we immunized WT and HIF1 / mice with the myelin oligodendrocyte glycoprotein (MOG) peptide emulsified in CFA. After 9 d, we isolated draining LN (DLN) cells and stimulated them with the MOG peptide ex vivo. Tritiated thymidine incorporation assays revealed that antigen-specific T cells from WT and HIF1 / mice proliferated to a similar (Zhou et al., 2008) . Thus, dysregulated IL-23R and Foxp3 expression in HIF1 / cells likely contributes to their impaired T H 17 differentiation.
To further understand how HIF1 regulates T H 17 differentiation, we compared gene expression profiles of WT and HIF1 / cells differentiated toward T H 17 cells using Affymetrix oligonucleotide arrays. A total of 581 probes showed equal or greater than twofold change (with false discovery rate <0.05) between WT and HIF1 / cells, including 194 up-regulated and 387 down-regulated entries upon HIF1 deficiency ( Fig. 2 F and Table S1 ). We analyzed the gene list for enrichment of gene ontology and canonical pathways using the DAVID bioinformatics databases (Huang da et al., 2009 ). Remarkably, the 10 pathways with the most significant enrichment were all associated with glycolytic or related metabolic pathways (Fig. S3) . Fig. 2 G showed the expression of a selective group of metabolic molecules, including the glycolytic 
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TGF- concentrations (Fig. 3 A) . Consistent with these findings, mRNA expression of Foxp3, as well as T reg cell-associated surface molecules such as Ctla4 and Gpr83, was up-regulated in HIF1 / cells (Fig. 3 B) . Furthermore, both in an in vitro T reg cell differentiation system mediated by splenic DCs (without exogenous cytokines) and in an ex vivo recall response after MOG immunization, HIF1 / T cells exhibited higher Foxp3 induction (Fig. 3, C and D) . Finally, HIF1 / cells showed a reduction of IL-17 expression and a reciprocal increase in Foxp3 levels under T H 17-polarizing conditions with titrated amounts of IL-6 (Fig. 3 E) . This is in agreement with the notion that the dichotomy of T H 17 and T reg cell is dependent on an inflammatory environment, especially the concentration of IL-6 (Bettelli et al., 2006) . Thus, HIF1 is required to promote T H 17 but to inhibit T reg cell differentiation.
Blocking glycolysis reciprocally alters T H 17 and T reg cell differentiation
Having established an essential role for HIF1 in controlling the balance between T H 17 and T reg cell differentiation, we next asked whether HIF1-dependent metabolic reprogramming is instrumental to such cell fate decision. Consistent with the selectively high glycolytic activity and HIF1 expression in T H 17 relative to T reg cells (Fig. 1, A and B) , real-time PCR degree (unpublished data). However, IL-17 expression was reduced in T cells isolated from HIF1 / mice (Fig. 2 H) . Moreover, we expanded the DLN cells with MOG and IL-23 and transferred the resulting cells into C57BL/6 mice. In this T H 17-polarized transfer model of EAE (Kang et al., 2010) , disease development was significantly delayed in mice receiving the HIF1 / cells comparing those receiving the WT cells (Fig. 2 I) . Histological analyses showed less prominent leukocyte infiltration and inflammation in the spinal cords of mice transferred with HIF1 / cells (Fig. 2, J and K) . Therefore, HIF1 is required for T H 17 differentiation in vivo and contributes to T H 17-dependent CNS inflammation.
The balance of T H 17 and T reg cell differentiation depends on HIF1
An abnormal up-regulation of Foxp3 mRNA expression in HIF1 / cells during T H 17 differentiation (Fig. 2 E) prompted us to test whether HIF1 controls the balance between the closely regulated T H 17 and Foxp3 + T reg cell lineages. Deficiency of HIF1 considerably increased the Foxp3 + population when naive T cells were activated in the presence of TGF-, with more prominent changes observed under low nonsaturating comparison, we treated T cells with the mTOR inhibitor rapamycin, which blocks mTOR-dependent metabolic pathways including glycolysis (Düvel et al., 2010; Powell and Delgoffe, 2010) . Similar to the effects of 2-DG, treatment of T cells with rapamycin inhibited the glycolytic activity and the production of IL-17 (Fig. 4, A and B) . Moreover, mRNA expression levels of T H 17-associated cytokines, including IL-17, IL-17F, IL-21, and IL-22, were all inhibited by 2-DG and rapamycin treatments (Fig. 4 C) . Notably, because the cells were treated with the pharmacological inhibitors during their differentiation but not at the time of acute restimulation of effector T H 17 cells, the diminished production of these T H 17 signature cytokines reflected a specific effect of glycolytic inhibition on the differentiation.
To test the effects of 2-DG on the development of T H 17 cells in vivo, we transferred naive T cells (CD62L hi CD44 lo ) from OT-II TCR-transgenic mice (specific for OVA 323-339 ; analyses revealed that the expression of metabolic genes involved in glycolysis was much higher in differentiating T H 17 cells than in T reg cells (Fig. 3 F) .
To directly test the importance of the metabolic reprogramming in T cell differentiation, we cultured naive T cells under T H 17-polarizing conditions in the presence or absence of 2-DG, a prototypical inhibitor of the glycolytic pathway via blocking hexokinase, the first rate-limiting enzyme of glycolysis. As expected, 2-DG treatment of T cells reduced the glycolytic activity (Fig. 4 A) . Importantly, treatment of T cells with 2-DG resulted in diminished production of IL-17 (Fig. 4 B) . Although high concentrations of 2-DG (10-50 mM) have been shown to inhibit T cell proliferation (Cham et al., 2008) , at the lower dose of 2-DG used in this study (1 mM), we observed minimal inhibitory effects of 2-DG on cell proliferation, as indicated by the indistinguishable CSFE dilution between control and 2-DG-treated samples (Fig. 4 B) . As a (Fig. 4 G) . When these cells were transferred into C57BL/6 recipients, 2-DGtreated cells exhibited markedly reduced ability to cause EAE (Fig. 4 H) . This was associated with diminished leukocyte infiltration and spinal cord inflammation, as revealed by histological analyses (Fig. 4, H and I; and Fig. S4 C) . Therefore, blocking glycolysis alters T H 17 and T reg cell differentiation and protects mice from EAE. mTOR is required for HIF1 induction in T H 17 cell differentiation A key role for HIF1 to direct reciprocal T H 17 and T reg cell differentiation prompted us to identify upstream molecular pathways responsible for HIF1 induction in differentiating T H 17 cells (Fig. 1 B) . Because cell fate decision between T H 17 and T reg cells is critically dependent on IL-6, we analyzed HIF1 expression in T cells stimulated with varying amount of IL-6. HIF1 was induced by IL-6 in a dose-dependent manner (Fig. 5 A) , indicating an important role for IL-6 signaling in HIF1 induction.
Recent experiments have shown that HIF1 is responsible for the glycolytic response downstream of mTOR (Düvel et al., 2010) . As rapamycin treatment was similar to HIF1 deficiency at altering T H 17 and T reg cell differentiation, we hypothesized that rapamycin-sensitive mTOR signaling is important for HIF1 induction in T cells. To test this, we treated T cells with rapamycin and examined HIF1 expression. Blocking mTOR activity with rapamycin in differentiating Thy1.1 + ) into C57BL/6 mice and immunized them with antigen, followed by daily 2-DG treatment in vivo. At day 6 after immunization, we isolated DLN cells and measured IL-17 production in donor-derived cells by intracellular cytokine staining. Treatment of 2-DG resulted in significantly reduced IL-17-expressing cells (Fig. 4 D) . Moreover, mRNA expression and secretion of IL-17 were considerably reduced after 2-DG treatment (Fig. S4, A and B) . We therefore conclude that T H 17 differentiation depends on the glycolytic activity.
We next examined the effects of 2-DG and rapamycin on T reg cell generation. Rapamycin has been shown to potentiate T reg cell differentiation (Haxhinasto et al., 2008; Sauer et al., 2008; Cobbold et al., 2009) . Similar to the effect of rapamycin, 2-DG also promoted T reg cell generation (Fig. 4 E) . Furthermore, under conditions that allowed simultaneous generation of T H 17 and T reg cells, 2-DG and rapamycin diminished IL-17 production but promoted Foxp3 induction (Fig. 4 F) . Collectively, these results indicate that inhibition of glycolysis blocks T H 17 development while promoting T reg cell generation.
To evaluate the contribution of glycolysis to autoimmune inflammation in vivo, we used the T H 17-polarized transfer sion program. Given the evolutionarily conserved nature of the hypoxic response and glycolytic pathway, we propose that the adaptive immune system has evolved to adopt these basic metabolic machineries to regulate cell fate decision of helper T cells. Furthermore, the selective dependence of T H 17 differentiation on HIF1-mediated metabolic reprogramming has provided novel targets for therapeutic intervention of autoimmune and inflammatory diseases elicited by T H 17 cells.
MATERIALS AND METHODS
Mice. HIF1 flox/flox and OT-II TCR-transgenic mice on the C57BL/6 background were purchased from The Jackson Laboratory (Ryan et al., 2000) . Mice at 7-12 wk of age were used. All mice were kept in specific pathogen-free conditions within the Animal Resource Center at St. Jude Children's Research Hospital. Animal protocols were approved by the Institutional Animal Care and Use Committee of St. Jude Children's Research Hospital.
Flow cytometry. For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) BSA and the appropriate antibodies from eBioscience. Foxp3 staining was performed according to the manufacturer's instructions (eBioscience). For intracellular cytokine staining, T cells were stimulated for 4-5 h with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of monensin before being stained according to the manufacturer's instructions (BD). Simultaneous Foxp3 and IL-17 staining was performed using Foxp3 staining procedure after 4 h of stimulation with PMA and ionomycin. Flow cytometry data were acquired on an upgraded five-color FACScan or multi-color LSRII (BD) and were analyzed with FlowJo software (Tree Star).
Cell purification and culture. Lymphocytes were isolated from spleen and peripheral LNs and naive T cells were sorted on a MoFlow (Beckman Coulter) or Reflection (i-Cyt), as described previously . Sorted naive T cells (CD4 + CD62L hi CD44 lo CD25  ) were used for in vitro culture in Click's medium (plus -mercaptoethanol) supplemented with 10% (vol/vol) FBS and antibiotics. T cells were activated with 2 µg/ml anti-CD3 (2C11; Bio X Cell), 2 µg/ml anti-CD28 (37.51; Bio X Cell), and 100 U/ml human IL-2. For T reg cell differentiation, cultures were supplemented with 1 or 10 ng/ml human TGF-1. For T H 1 conditions, 3.5 ng/ml IL-12 and 10 µg/ml anti-IL-4 (11B11; Bio X Cell) were added. For T H 2 conditions, 10 ng/ml IL-4 and 10 µg/ml anti-IFN- were added. For T H 17 conditions, 10 µg/ml anti-IL-2, 10 µg/ml anti-IL-4, 10 µg/ml anti-IFN-, 2 ng/ml TGF-1, 20 ng/ml IL-23, and 20, 2, or 0.2 ng/ml IL-6 were included in cultures, and for certain experiments, only TGF-1 and IL-6 were used, as indicated. For DC-T cell co-culture, 5 × 10 4 CD11c + DCs purified from spleens and 2.5 × 10 5 naive T cells were cultured in the presence of anti-CD3 without exogenous cytokines. For pharmacological inhibitor treatments, cells were incubated with vehicle, 0.5-1 mM 2-DG (SigmaAldrich), or 10-50 nM rapamycin (EMD) at the onset of cultures.
RNA and immunoblot analysis. RNA was extracted with an RNeasy kit (QIAGEN), and cDNA was synthesized with Superscript III/II reverse transcription (Invitrogen). Real-time PCR was performed as described previously (Liu et al., 2009) , and the expression of each target gene is presented as the fold change relative to the expression of WT control samples. Primer sequences used to determine expression of glycolytic molecules were: HIF1 (forward, 5-AGCTTCTGTTATGAGGCTCACC-3; reverse, 5-TGAC-TTGATGTTCATCGTCCTC-3), Glut1/Slc2a1 (forward, 5-CAGTTC-GGCTATAACACTGGTG-3; reverse, 5-GCCCCCGACAGAGAA-GATG-3), HK2 (forward, 5-TGATCGCCTGCTTATTCACGG-3; reverse, 5-AACCGCCTAGAAATCTCCAGA-3), LDH- (forward, 5-CATTGTCAAGTACAGTCCACACT-3; reverse, 5-TTCCAATTA-CTCGGTTTTTGGGA-3), PKM (forward, 5-GCCGCCTGGACATT-GACTC-3; reverse, 5-CCATGAGAGAAATTCAGCCGAG-3), MCT4
T H 17 cells markedly inhibited the induction of HIF1 (Fig. 5 B) . Consistent with these findings, the induction of transporters Glut1 and MCT4, as well as various glycolytic enzymes, was substantially diminished by rapamycin treatment (Fig. 5 C) . In contrast, 2-DG treatment, at the dose that was sufficient to alter T H 17 and T reg cell differentiation, had a minimal effect on the RNA levels of HIF1 and the metabolic molecules (Fig. S5, A and B) . This result confirmed a role for 2-DG to directly inhibit glycolytic enzyme activity and excluded a potential indirect effect of 2-DG on regulating mTOR activity. Consistent with a high glycolytic activity in T H 1 and T H 2 lineages (Fig. 1 A) , 2-DG treatment was also capable of diminishing their differentiation (Fig. S5 C) . Although mTOR is required for the generation of T H 1 and T H 2 cells ), HIF1 was not strongly induced under T H 1-and T H 2-polarizing conditions (Fig. 1 B) or involved in their functional differentiation (Fig. S2 C) . Collectively, HIF1 is selectively expressed in T H 17 cells and its induction depends on IL-6 signaling and mTOR activity, whereas the glycolytic pathway contributes to T H 1 and T H 2 differentiation in a HIF1-independent manner.
Collectively, our studies demonstrate that an elevated glycolytic activity is not only associated with T H 17 cell differentiation but that the glycolytic machinery is actively regulated to direct the differentiation of T H 17 and T reg cells. This process is programmed by the transcription factor HIF1 through stimulating a glycolytic gene expression program. Therefore, the HIF1-dependent glycolytic pathway serves as a metabolic checkpoint to distinguish cell fate decision between these two closely related T cell lineages. We provide further evidence that mTOR signaling is essential to induce HIF1 expression in T H 17 cells, suggesting that the HIF1-dependent glycolytic pathway is an integral component downstream of mTOR to mediate T H 17 and T reg cell differentiation (Fig. 5 D; Delgoffe et al., 2009; Powell and Delgoffe, 2010) . In contrast, deficiency of HIF1 did not substantially alter T H 1 and T H 2 differentiation, indicating a HIF1-independent glycolytic pathway for the generation of these effector lineages. Interestingly, depletion of amino acids with the small molecule halofuginone has recently been shown to selectively inhibit T H 17 cell differentiation (Sundrud et al., 2009) . Therefore, T H 17 cell differentiation has selective bioenergetic requirements for glucose and amino acid metabolism. Conversely, generation of antigen-specific T reg cells is enhanced by amino acid depletion (Cobbold et al., 2009) or inhibition of glucose metabolism (this study). Recently added evidence further suggests that T reg cells preferentially use fatty acids and inhibition of fatty acid -oxidation impairs T reg cell differentiation (Michalek et al., 2011) . Notably, although overexpression of HIF1 has been shown to enhance Foxp3 expression (Ben-Shoshan et al., 2008) , our results with HIF1-deficient and 2-DG-treated T cells have clearly established a negative role for HIF1-induced metabolic reprogramming in T reg cell development. To our knowledge, these studies identify the first evidence that the glycolytic pathway and helper T cell differentiation are linked by the HIF1-mediated gene expres-In vivo antigen-specific T H 17 differentiation. C57BL/6 mice were injected i.p. with 2-DG (2 g/kg body weight) or solvent alone (PBS). After 6 h, approximately one million naive T cells (CD4 + CD62L hi CD44 lo CD25 -) from OT-II TCR-transgenic mice (Thy1.1 + ) were injected into these mice via tail vein. After 24 h, they were immunized s.c. with 100 µg OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] in the presence of incomplete Freund's adjuvant (Difco). Mice were sacrificed at day 6 after immunization, and DLNs were isolated and either stimulated with the cognate peptide for 2-3 d for RNA assay or secreted cytokine measurement or pulsed with PMA and ionomycin for 5 h for intracellular staining for donor-derived T cells (Thy1.1 + ). 2-DG/PBS was given daily until the day before the mice were euthanized.
MOG immunization and T H 17-polarized transfer EAE.
Mice were immunized with 100 µg MOG peptide in CFA (Difco) with 500 µg Mycobacterium tuberculosis. After 9 d, DLNs were prepared and cultured for 5 d with MOG and IL-23 and, where applicable, 1 mM 2-DG was included. Live cells were harvested at the end of culture, and 2 × 10 7 cells were transferred into mice that were irradiated sublethally (500 Rad) 4 h before transfer, supplemented by i.p. injections of 200 ng pertussis toxin on the day of transfer and 2 d later, as previously described (Kang et al., 2010) . The mice were observed daily for clinical signs and scored as described previously (Chi and Flavell, 2005) .
Histopathology and immunohistochemistry.
Mice were euthanized on day 11-12 after transfer, and spinal cords were fixed by immersion with 10% neutral buffered formalin solution and decalcified. Fixed tissues were embedded in paraffin, sectioned, and stained with H&E, with serial histological sections stained immunohistochemically to determine the distribution and types of inflammatory cells in the brain and spinal cord. For immunohistochemical detection of T cells, goat polyclonal primary antibodies against CD3 (Santa Cruz Biotechnology, Inc.) was used at a 1:350 on tissue sections subjected to antigen retrieval for 30 min at 98°C (Target Retrieval, pH 6; Dako). Similarly, to detect macrophages and other myeloid cells in the CNS, a rat monoclonal primary antibody against Mac2 (Accurate Chemical) was used at a 1:20,000 on tissue sections subjected to antigen retrieval for 30 min at 98°C (Citrate buffer, pH 6; Invitrogen). Spinal cord pathology was assigned scores by an experienced pathologist (P. Vogel) as follows: spinal column was divided into cervical (two to three sections), thoracic (three to five sections), and lumbar (three to five sections) and was scored for inflammatory and degenerative lesions (mononuclear perivascular cuffing, gliosis, vacuolation caused by swollen axon sheaths, and polymorphonuclear infiltration) according to the predetermined qualitative and semiquantitative criteria of 0 = absence of lesions, 1 = minimal to mild inconspicuous lesions, 2 = conspicuous lesions, 3 = prominent multifocal lesions, and 4 = marked coalescing lesions. Sections from animals in different groups were scored in staggered order to prevent score bias.
Gene expression profiling by microarray analysis. RNA samples in biological triplicates were analyzed using the GeneTitan peg array (HT_MG-430_PM; Affymetrix) and expression signals were summarized using the RMA algorithm (Expression Console version 1.1; Affymetrix). Differentially expressed transcripts were identified by ANOVA (Genomics Suite version 6.5; Partek), and the Benjamini-Hochberg method was used to estimate the false discovery rate (Benjamini and Hochberg, 1995) . Gene lists were analyzed for enrichment of Gene Ontology and canonical pathways using the DAVID bioinformatics databases (Huang da et al., 2009 ). The entire
